# Post-authorization Safety Study of Iptacopan in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Using Data From the IPIG PNH Registry

> **NCT06903234** · — · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 200 (estimated)

## Conditions studied

- Hemoglobinuria, Paroxysmal

## Interventions

- **DRUG:** Iptacopan

## Key facts

- **NCT ID:** NCT06903234
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-31
- **Primary completion:** 2029-10-01
- **Final completion:** 2029-10-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06903234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06903234, "Post-authorization Safety Study of Iptacopan in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Using Data From the IPIG PNH Registry". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06903234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*